FDA warns Yiling Pharmaceutical over manufacturing violations causing cross-contamination risks in finished drugs from shared equipment.
What happened
FDA inspected Yiling Pharmaceutical's finished-drug facility in Shijiazhuang, Hebei, China, from October 7 to 11, 2024. Investigators found non-dedicated equipment with drug residues in ducts and degraded seals covered with tape, creating potential cross-contamination, including with highly potent drugs. FDA also found the quality unit failed to ensure adequate cleaning and oversight.
What FDA found
The company used non-dedicated manufacturing equipment that was not designed or maintained to prevent cross-contamination; drug residues were found and duct seals were degraded and covered with tape.
21 CFR 211.63The quality unit failed to ensure adequate cleaning procedures, including disassembly and visual inspection of equipment ducts, so visible residue and possible cross-contamination were not identified.
21 CFR 211.22The quality unit did not adequately oversee manufacturing to ensure drug products met identity, strength, quality, and purity requirements.
21 CFR 211.22The company's response was inadequate because its cross-contamination assessment tested reserve samples only for the preceding drug substance, not all drug substances processed on the shared equipment.
What FDA wants
FDA tells Yiling to correct the violations promptly and respond in writing within 15 working days with corrective action plans, risk assessments, and cleaning and quality-unit remediation. FDA may withhold approval of new applications, re-inspect, or refuse US admission if the violations are not addressed.
Who should pay attention
- brands that buy finished drugs from this contract manufacturer
- US importers and distributors of Yiling drug products
- drugmakers sharing equipment for highly potent products
This is a summary. Read the original letter on fda.gov.